Wiseguyreports.Com Adds “Cancer Biological Therapy -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023” To Its Research Database
Cancer is the leading and second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and such other factors. There are many biological therapies that have been approved and being used by various cancer specialists across the globe. While there are many other therapies also which are under the research and development phase and are yet to be available for commercial use.
Biological therapy treatment is treatment process which is performed with the help of living organisms, parts of living organisms or laboratory manufactured version of such content. Most of the biological therapies uses bacteria or vaccines to mimic the body’s immune system to act against cancer developing cells. These various types of biological therapies, which are most of the times stated to biological response modifier therapy or immunotherapy, but these types of therapies do not always target cancer cells directly. Further there are other biological therapies like sections of genetic material or antibodies which are commonly known as DNA or RNA, do aim at targeting cancer cells directly. There are some other types of biological therapies that inhibit specific molecules involved in development and growth of cancer tumor. Such therapies known as cancer targeted therapies.
The Europe, Middle East and Africa Cancer Biological Therapy market is expected to reach US$ 29,776.3 million by 2023 at a CAGR of 5.0% during the forecast period.
EMEA Cancer Biological Therapy Market is further segmented into type of therapy which include Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Cancer Growth Blockers, Interferons, Interleukins, Gene Therapy, Targeted Drug Delivery, Colony Stimulating Factor, Cancer Vaccines and other therapies. The Monoclonal Antibodies segment includes sub segment namely Naked Monoclonal Antibodies. Interferon segment is further sub segmented into Alpha Interferon, Beta Interferon and Gamma Interferon.
On the basis on end users cancer biological therapy market is segmented into Hospitals & Clinics, Laboratories, Cancer Research Centers and other end users. Hospitals & Clinics accounted for the largest market share of EMEA cancer biological therapy market. Hospitals & Clinics commands maximum share of EMEA cancer biological therapy market in 2015.
On the basis of region, Europe accounted for the largest market share in biological therapy market. While Middle East and Africa region is expected to grow with a steady pace during forecast period.
The leading market players in the Europe, Middle East and Africa Cancer Biological Therapy market include Amgen Inc., Bristol-Myers Squibb, Celgene Corporation, ELI Lilly and Company, EnGeneIC Ltd., EnGeneIC Ltd., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis, Pfizer Inc, Seattle Genetics Inc. and Teva Pharmaceutical Industries Ltd.
Study objectives of Cancer Biological Therapy market:
Ø To provide insights about factors influencing and affecting the market growth
Ø To provide historical and forecast revenues of the market segments and sub-segments with respect to regional and country-level markets
Ø To provide historical and forecast revenue of the market segments based on type of therapy, end users, and its sub-segments.
Ø To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
• Medical devices distributors
• Hospitals & Clinics
• Potential investors
• Key executive (CEO and COO) and strategy growth manager
• Pharmaceutical companies
• Europe accounted for the largest market share of monoclonal antibodies cancer biological therapy market, registering $5,316.8 million in 2015 and expected to reach at $6,844.1 million by 2021
• Targeted Therapy is the fastest growing segment with a CAGR of and 5.7% in EMEA
• Cancer growth blockers is contributing remarkable share towards the market registering $4,990.5 million in 2015
The reports also covers regional analysis:
• Western Europe
• Rest Of Europe
• Middle East
• Gulf Cooperation Council (GCC)
§ Saudi Arabia
• Rest of Middle East
Contact Us: [email protected] Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)
P: +44 208 133 9349
M: +1 646 845 9349